PROJECT SUMMARY/ABSTRACT: Core 2
We will establish a core facility for in vivo cancer modeling and screening. This core facility (core 2 in the
cancer systems biology center) will consist of several sets of functional components, defined as modules,
including vector design and genome-scale library construction, large-scale cell culture and virus production,
tumor transplantation and in vivo pooled screening, CRISPR/Cas9 mediated somatic genome editing for
invasive phenotype analysis. In preliminary studies, we have applied in vivo somatic genome editing to
generate tumor models of specific driver genes in mice, and demonstrated in vivo screening in a lung
metastasis animal model. We will build four modules in this core, including the following: Module 1. Facility
for vector design and genome-scale library construction. This module supports functional investigations of
the mammalian genome that can reveal how genetic alterations lead to changes in phenotype, for example
cellular invasiveness phenotype described in the Projects 1 and 2. Module 2. Facility for large-scale cell
culture, viral vector production and transduction. This will serve for two purposes: (1) generation of
customized viral particles for in vivo studies involving animals models for Projects 1 and 2 as well as other
collaborators; (2) high-throughput screening applications that requires transduction of a population of cells with
highly complex libraries. Module 3. Facility for tumor transplantation and in vivo pooled screening. This
module will setup a facility with two capacities: (1) tumor transplantation and (2) in vivo pooled screening. This
will serve for the purpose of validating the genes discovered in the projects in mouse models, to discover new
genes with invasive phenotypes using in vivo screens, or to enable collaborative research for discovery of new
drug targets. Module 4. Facility for CRISPR/Cas9 mediated somatic genome editing, for somatic genome
editing in various animals for virtually any loci in the mouse genome. We will establish this platform and utilize
it for research described in the projects and for setting up collaborations with various Yale investigators.
Specifically, we will utilize CRISPR library approach in conjunction with the Rapid Analysis of Cell migration
Enhancement (RACE) system described in the Projects, to identify how genetic alterations lead to changes in
cellular invasiveness phenotype. In addition, we will utilize these modules in the core to build novel models of
WNK1, NKCC1 and their targets, as well as combinations of mutant ERK, AKT and downstream genes. In
summary, this core will be tightly integrated into the U54 center, provide a powerful technology and resource
platform for in vivo cancer systems biology, and support Research Projects in the center as well as other
collaborators at Yale and the wider scientific community. Since there is no facility currently existing at Yale
providing similar functions, this new core will facilitate the establishment of the first in vivo cancer modeling and
screening core facility at Yale. We will also utilize this core facility for promoting education and training, serving
as a base for education of cancer researchers, scientists, students, and the general public.
No Sub Projects information available for 1U54CA209992-01 8697
Publications
Publications are associated with projects, but cannot be identified with any particular year of the project or fiscal year of funding. This is due to the continuous and cumulative nature of knowledge generation across the life of a project and the sometimes long and variable publishing timeline. Similarly, for multi-component projects, publications are associated with the parent core project and not with individual sub-projects.
No Publications available for 1U54CA209992-01 8697
Patents
No Patents information available for 1U54CA209992-01 8697
Outcomes
The Project Outcomes shown here are displayed verbatim as submitted by the Principal Investigator (PI) for this award. Any opinions, findings, and conclusions or recommendations expressed are those of the PI and do not necessarily reflect the views of the National Institutes of Health. NIH has not endorsed the content below.
No Outcomes available for 1U54CA209992-01 8697
Clinical Studies
No Clinical Studies information available for 1U54CA209992-01 8697
News and More
Related News Releases
No news release information available for 1U54CA209992-01 8697
History
No Historical information available for 1U54CA209992-01 8697
Similar Projects
No Similar Projects information available for 1U54CA209992-01 8697